CVRx (NASDAQ:CVRX) Rating Lowered to Sell at Wall Street Zen

Key Points

• CVRx was downgraded to “sell” by Wall Street Zen, while several other analysts also lowered their ratings. The overall consensus remains “hold,” with a $6.90 price target versus the stock’s $2.39 price.
• Shares have fallen nearly 60% and trade close to their 12-month low, reflecting concerns about profitability and execution. CVRx reported a quarterly loss of $0.53 per share, negative margins, and analysts expect a full-year loss.
• Management cut revenue guidance, forecasting third-quarter revenue of $13.5 million–$14.5 million and full-year 2026 revenue of $58 million–$60 million, citing slower sales productivity and Medicare Advantage headwinds.

CVRx (NASDAQ:CVRX - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

Several other analysts also recently weighed in on the stock. Piper Sandler downgraded shares of CVRx from an "overweight" rating to a "neutral" rating and set a $4.00 price objective for the company. in a research report on Friday. Lake Street Capital downgraded shares of CVRx from a "buy" rating to a "hold" rating and set a $3.50 target price on the stock. in a research report on Friday. Weiss Ratings reiterated a "sell (e+)" rating on shares of CVRx in a research note on Monday. Canaccord Genuity Group reissued a "buy" rating and issued a $10.00 price target on shares of CVRx in a research report on Tuesday, April 14th. Finally, Craig Hallum downgraded shares of CVRx from a "buy" rating to a "hold" rating and set a $4.00 price objective for the company. in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $6.90.

CVRx Stock Down 59.8%

Shares of NASDAQ CVRX opened at $2.39 on Friday. The stock has a market cap of $63.43 million, a P/E ratio of -1.21 and a beta of 0.81. The company has a current ratio of 10.20, a quick ratio of 8.89 and a debt-to-equity ratio of 2.01. CVRx has a 12-month low of $2.30 and a 12-month high of $11.30. The business's fifty day simple moving average is $5.19 and its 200-day simple moving average is $6.49.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.01). CVRx had a negative net margin of 84.93% and a negative return on equity of 133.84%. The firm had revenue of $15.71 million during the quarter, compared to analyst estimates of $15.55 million. As a group, equities analysts predict that CVRx will post -1.89 EPS for the current fiscal year.

Institutional Trading of CVRx

Institutional investors have recently modified their holdings of the business. Larson Financial Group LLC raised its position in CVRx by 155.6% in the fourth quarter. Larson Financial Group LLC now owns 5,426 shares of the company's stock worth $39,000 after acquiring an additional 3,303 shares in the last quarter. Deutsche Bank AG acquired a new stake in CVRx in the second quarter valued at $62,000. R Squared Ltd purchased a new stake in shares of CVRx during the 4th quarter worth $74,000. Virtu Financial LLC purchased a new stake in shares of CVRx during the 4th quarter worth $79,000. Finally, Corient Private Wealth LLC acquired a new position in shares of CVRx during the 4th quarter worth $81,000. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

Key CVRx News

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, slightly above the $15.55 million analyst consensus. Its per-share loss of $0.53 was also an improvement from a $0.57 loss a year earlier, although it narrowly missed the $0.52 consensus loss. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Despite downgrading the shares to “hold,” Lake Street Capital and Craig Hallum set price targets of $3.50 and $4.00, respectively—above the current trading level—suggesting potential recovery if execution improves. The Fly analyst ratings
• Neutral Sentiment: Johnson Fistel said it is investigating whether CVRx or certain executives violated securities laws in connection with the guidance reduction and sales-execution disclosures. The announcement is an investigation notice, not a finding of wrongdoing, but it adds headline and legal risk. Johnson Fistel investigation notice
• Negative Sentiment: CVRx cut third-quarter revenue guidance to $13.5 million-$14.5 million, well below the $16.9 million consensus, and reduced full-year 2026 revenue guidance to $58 million-$60 million from an implied level near the $65.4 million consensus. Management cited slower sales productivity and Medicare Advantage-related headwinds. CVRx forecasts 2026 revenue
• Negative Sentiment: The quarterly loss slightly exceeded expectations, while CVRx continues to report deeply negative profitability, including a negative net margin and negative return on equity. Analysts responded by downgrading the stock from “buy” to “hold,” reinforcing concerns about near-term growth and execution. CVRx Q2 2026 earnings call transcript

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company's flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body's natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source